Jerel Davis

Managing Director

Jerel Davis picture

Jerel Davis

Versant Ventures

Managing Director

Since joining Versant in 2011, Jerel Davis has been involved in launching and investing in a number of Versant’s portfolio companies including BlueRock (sale), Crispr (public 2016), Inception 4 (sale), Inception 5 (sale), Quanticel (sale), Akero (public 2019), Northern (sale), Repare (public 2020), Chinook (public 2020), Turnstone, Ventus, Graphite Bio, Rayze, and Tentarix. He has led company creation and creative corporate transactions with multiple pharmaceutical partners, and was instrumental in establishing Versant’s presence in Canada. Prior to joining Versant, Jerel was an Associate Principal at McKinsey and Company where he advised healthcare corporations in pharmaceuticals, biotechnology, medical device and molecular diagnostics. He has worked in a number of healthcare markets globally including the U.S., Canada, Europe, China, Russia and India. Jerel was a post-doctoral fellow at Stanford University, where he also completed his Ph.D., and trained at Amgen as a researcher.